Abstract
Increasingly successful protocols enabling HLA antibody incompatible renal transplantation have resulted in a rise in the incidence of antibody mediated rejection. There are limited options to treat this feared complication. Eculizumab, a potent inhibitor of the complement cascade, has recently been suggested as a possible addition to treatment of AMR. We report the use of eculizumab in three very high risk transplant recipients.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
